Tessa Jaspers and Colleagues on Current Evidence Not Supporting Routine Anti-Xa Monitoring in Use of LMWH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins
LMWHs are widely used in diverse patient groups (renal impairment, pregnancy, obesity), but the value of anti-Xa monitoring remains unclear.
This systematic review of 48 studies (RCTs and observational) found:
- Comparable bleeding and VTE rates in monitored vs. unmonitored patients.
- Frequent dose adjustments in monitored cohorts.
- Weak or absent correlation between anti-Xa levels and clinical outcomes.
Current evidence does not support routine anti-Xa monitoring for LMWH dose adjustment.”
Read the full paper in JTH.
Article: A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins
Authors: Tessa C. C. Jaspers, P. Christian Remmelzwaal, Eefje P.S. Weersink, Karina Meijer, Nakisa Khorsand

Stay updated on all science in the field of anticoagulation with Hemostasis Today.
-
Sep 6, 2026, 05:58Mohamed F Doheim: ‘Stroke as a Symphony’ – Rethinking Decision-Making in Acute Ischemic Stroke
-
Sep 6, 2026, 05:26Yousef Hindi: Unprovoked Left Renal Vein Thrombosis and Severe IDA – Long-Term Resolution and Dual-Energy CT Findings
-
Sep 6, 2026, 05:18Robert Brown: Standardizing Amniotic Fluid Embolism Diagnosis – SMFM and AFE Foundation Criteria
-
Sep 6, 2026, 04:45Mohammed Al Kanan: Early Identification of VTE Risk in Lung Cancer Patients
-
Sep 6, 2026, 04:38M. Ibrahim Siddique: Does Routine Triple Therapy Pay Off After Anterior STEMI?
-
Sep 6, 2026, 04:29Sandra Revill Tremulis: The Lp(a)HORIZON Topline Results Raise Important Questions Beyond Simply ‘Does Lowering Lp(a) Work?’
-
Sep 5, 2026, 19:20Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX